Objective 
Introduction
Asthma is defined as a chronic inflammatory disorder of the airways which manifests itself as recurrent episodes of wheezing, breathlessness, chest tightness and cough. It is characterized by bronchial hyper responsiveness and variable airflow obstruction, that is often reversible either spontaneously or with treatment. 1 Nocturnal asthma is defined by a drop in forced expiratory volume in 1 second (FEV1) of at least 15% between bedtime and awakening in patients with clinical and physiologic evidence of asthma. Nocturnal asthma is associated with a circadian pattern in lung function, distal airway inflammation, glucocorticoid receptor affinity, pulmonary capillary blood volume, and beta-2 adrenergic receptor function may also contribute. 2 Nocturnal asthma is common and approximately 30 to 70 percent of patients with asthma report nocturnal asthma symptoms at least once a month. 3, 4 The occurrence of nocturnal asthma symptoms is also reflected in mortality statistics. As an example, over a one-year period, 53 percent of asthma deaths in one report occurred at night. 5 As many as 75% of asthmatic subjects are awakened by asthma symptoms at least once per week, with approximately 40% experiencing nocturnal symptoms on a nightly basis. An extensive body of research has demonstrated that nocturnal symptoms of cough and dyspnea are accompanied by circadian variations-in airway inflammation and physiologic variables, including airflow limitation and airways hyper responsiveness. Nocturnal worsening of asthma is a well-described and important problem that must be considered in the management of patients with asthma 6 . In particular, nocturnal asthma symptoms are felt to be a characteristic feature of asthma that is not well-controlled 7, 8 .
Increasing awareness of the exaggerated circadian rhythm in bronchomotor tone that causes most asthmatic patients to have increase respiratory symptoms in the early morning has resulted in a search for such a sustained release molecule with superior dosing strategy that will provide maximal bronchodialatory activity at the time of reduced bronchial patency.
Objective of this Study
The objective of this study to observe the improvement in Nocturnal Asthma symptoms and Quality of Life (QoL) with administration of once daily sustained release theophylline preparation.
Materials and methods:
Sample size: A total of 70 patients with choronic persistent asthma, both sex, age > 18 to 50 years of age and preferably patients with nocturnal exacerbations were included in the study. March 2017 to August 2017 in Shaheed Suhrawardy Medical College Hospital, Dhaka.
Each patient underwent recording of medical, occupational, and smoking history; physical examination; chest radiography and spirometry as screening tests to ensure that they met the inclusion criteria. The spirometry was performed before and 20 minutes after inhalation of a bronchodilator at the first visit. Dyspnea was scored using the British MRC dyspnea scale (Moor-Jankowski 1976). Patients who met all the criteria were enrolled in study. The patients had been receiving sustained release of theophylline at evening. None of the patients was treated with anti-histamines, anti-leukotrienes, cromolyn, β-blockers, ACE inhibitors, oral prednisolone, and/or LABAs during the study. Some of the patients had discontinued these medications at least 4 weeks before enrollment. Patients were excluded if they had experienced an exacerbation within 4 weeks before enrollment. The use of a short-acting β 2 -agonist or short-acting anticholinergic on demand was permitted. Physical examinations, spirometry, and MRC scoring, were performed at screening and baseline, and after 4 and 8 weeks of treatment. Regarding number of exacerbation free night, It was observed that 65(92.86%) was found exacerbation free night and 5(7.14%) patients were found exacerbation. There were significantly improved FEV1 between 1st follow up to 2nd follow up, 3rd follow up and 4 th follow up. Here p<0.001, which was statistically significant. night and 5 (7.14%) patients were found exacerbation. Yiin KT, et al. 9 found that administration of Uniphyllin (10 mg/ kg) once a day at 6 PM could maintain the blood level of theophylline within therapeutic range at least 12 to 24 hrs. The peak expiratory flow rate of the 6 cases we collected, were significantly improved.
Results
It was observed that duration of undisturbed sleep at night 33 (47.1%) was found < 3 months, 26(37.1%) was between 4-5 months and 11(15.7%) was between 6 of months. Direct effects of sleep on breathing, such as changes in breathing pattern 10 and ventilator control 11, 12 are transient and on arousal return to the patterns found in wakefulness.
There are significantly improved qualities of life between 1 st follow up to 2 nd follow up, 3 rd follow up and 4 th follow up p<0.001 which was statistically significant. Helm SG and Meltzer 13 study found once-daily regimen of controlled release theophylline (Uniphyl tablets) with previous twice-or thrice-daily methylxanthine regimens. Three hundred asthmatic patients, 78 percent prone to nocturnal episodes during prior therapy, completed the investigation. Eighty-two percent of the patients were treated for moderate or severe disease. After a one-week evaluation of baseline theophylline therapy (with adjunctive medication), the patients substituted evening doses of the once-daily drug in approximate milligram-for milligram equivalent doses. Concomitant medications were allowed as before. Nighttime and morning asthma control improved significantly without deterioration in the evening, and without increased side effects. Once daily therapy resulted in markedly fewer night awakenings involving inhaler use (p <0.01) and near 60 percent reductions in the number of patients with night time or early morning exacerbations (p<0.01) Control of morning chest tightness, wheeze, and dyspnea Improved significantly (p<0.01) and patients' as well as investigators' global evaluations favored once-daily treatment (p<0.01) Morning peak expiratory flow rates improved both at home (p<0.01) and at the office (p = 0.05). The forced expiratory volume in one second at the office increased modestly in the entire group. It is concluded that Uniphyl is effective and well tolerated when administered in once-daily evening doses.
FEV1 measurements in patients treated with theophylline were significantly improved compared with those observed in patients treated with placebo at treatment week 8 and week 12 (p=0.004); these changes represented 8 and 16% improvements from baseline with placebo and theophylline, respectively, at week 12. Janson et al. 14 
2nd-FEV1-4th-FEV1
Discussion
Regarding number of exacerbation free night, It was observed that 65 (92.86%) was found exacerbation free percentage of the predicted value (%FEV1). There was also significant correlation between increasing age and decreasing % FEV I (P less than 0.01). Kawayama et al. 15 study observed that FEV I in the combinationgroup, but not in the theophylline alone, was significantly increased at 4 (1.56 ± 0.13 L, p <0.001) and 8 weeks (1.60 ± 0.13 L, p <0.001) from the baseline (1.40 ± 0.12 L). In the combination group, but not the theophylline alone group, the dyspnea score was significantly improved after 4 (p <0.01) and 8 weeks (p < 0.05) compared with baseline.
Conclusion
Most of the patients were found exacerbation free night with sustained release theophylline. There was significantly improved quality of life between 1 st follow up to 2 nd follow up, 3 rd follow up and 4 th follow up. The value of FEV1 3 rd was gradually improved in 1st visit to 2 nd visit, 3 rd visit and 4 th visit. p<0.001 that was statistically singnificant
